Atopic keratoconjunctivitis

Atopic keratoconjunctivitis (AKC) is a chronic, bilateral inflammatory condition of the eyes that occurs in association with atopic dermatitis (eczema). It is considered one of the most severe forms of allergic eye disease and primarily affects the conjunctiva (the membrane lining the eyelids and covering the white of the eye) and the cornea. AKC typically develops in individuals who have a history of systemic atopic disease, including atopic dermatitis, asthma, or allergic rhinitis. The condition is driven by a complex interplay of IgE-mediated and T-cell-mediated immune responses. Key symptoms include intense itching, burning, tearing, and mucoid or ropy discharge from the eyes. Patients often experience significant eyelid involvement with thickening, scaling, and crusting of the lid margins (blepharitis). The conjunctiva may show papillary hypertrophy, scarring, and fibrosis, particularly of the tarsal (inner eyelid) conjunctiva. Corneal complications are common and can be sight-threatening, including punctate epithelial erosions, corneal neovascularization, ulceration, scarring, and keratoconus. Patients are also at increased risk for cataracts (particularly anterior subcapsular cataracts), herpes simplex keratitis, and secondary bacterial infections such as staphylococcal blepharitis. Treatment of AKC involves a multimodal approach. First-line therapies include avoidance of known allergens, cold compresses, and preservative-free artificial tears for lubrication. Topical antihistamines and mast cell stabilizers (such as olopatadine) are commonly used. For moderate to severe disease, topical corticosteroids may be required for acute flares, though long-term use is limited by the risk of glaucoma and cataracts. Topical calcineurin inhibitors such as tacrolimus and cyclosporine have become important steroid-sparing agents for chronic management. Systemic immunosuppressive therapy or biologic agents (such as dupilumab) may be considered in refractory cases. Management of concurrent atopic dermatitis and lid hygiene are essential components of care. Despite treatment, AKC can lead to progressive visual impairment if corneal complications are not adequately controlled.

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Common questions about Atopic keratoconjunctivitis